Softwr

Research · head to head

Dotmatics vs Seven Bridges

Dotmatics logo

Dotmatics

Research

Research informatics group behind GraphPad Prism, SnapGene, Geneious and LabArchives, now owned by Siemens

From
On request
Rated
-
Full reviewWebsite
Seven Bridges logo

Seven Bridges

Research

Cloud bioinformatics platform and trusted research environment, sold by Velsera

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Dotmatics the portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.; Seven Bridges the parent merged into Velsera in 2023 alongside Pierian and UgenTec, so the platform now competes for roadmap attention with clinical interpretation and diagnostics products inside a private equity owned group.
  • They diverge on capability: Dotmatics covers Dotmatics platform, Seven Bridges covers Trusted research environment.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Dotmatics and Seven Bridges actually diverge.

Attributes where Dotmatics and Seven Bridges differ
AttributeDotmaticsSeven Bridges
PlatformsWeb, Windows, macOS, On-premiseWeb, API, Cloud

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Dotmatics

  • Dotmatics platform
  • GraphPad Prism
  • SnapGene
  • Geneious Prime and Biologics
  • LabArchives
  • Flow cytometry tools
  • Protein Metrics
  • Siemens ownership

Only in Seven Bridges

  • Trusted research environment
  • Cloud-agnostic
  • CWL pipelines
  • Compliance certifications
  • Cost prediction
  • Public data commons
  • Collaboration
  • Tool library

What people use each for

The jobs each tool is most often brought in to do.

Dotmatics

  • A pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layernot Seven Bridges
  • A biotech that already owns Prism, SnapGene and Geneious separately and wants to understand what a group contract would covernot Seven Bridges
  • A university licensing LabArchives across departments as an institutional electronic lab notebooknot Seven Bridges
  • A biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement routenot Seven Bridges

Seven Bridges

  • A cancer genomics group analysing controlled-access dbGaP data that cannot be moved to local infrastructurenot Dotmatics
  • A federal or federally funded programme that needs FedRAMP Moderate authorisation for its analysis environmentnot Dotmatics
  • A multi-institution consortium sharing pipelines and results under defined access controls rather than by emailing filesnot Dotmatics
  • A diagnostics developer building reproducible CWL pipelines that must stand up to later regulatory reviewnot Dotmatics

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Dotmatics

  • The portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.
  • The Siemens acquisition completed in July 2025 with stated revenue synergy targets, which usually translates into pressure to move individually bought desktop licences into larger platform agreements, and small buyers of a single Prism or SnapGene seat should expect that pressure at renewal.
  • Nothing about the enterprise platform is publicly priced, and even the individual applications are increasingly moved to subscription, so total cost across a research group is hard to establish before negotiation.
  • Each acquired product retains its own licence terms, support channel and release cycle, so an organisation using four Dotmatics brands manages four different renewal dates, entitlement models and support experiences.
  • Enterprise deployments require data migration and configuration services, and validated instances for regulated use add both cost and an ongoing customer revalidation duty after each release, so the informatics platform is a programme rather than a purchase.

Seven Bridges

  • The parent merged into Velsera in 2023 alongside Pierian and UgenTec, so the platform now competes for roadmap attention with clinical interpretation and diagnostics products inside a private equity owned group.
  • Pricing is not published and splits into a platform subscription plus consumption-based cloud compute, so a heavy analysis quarter produces a bill that headcount-based budgeting does not anticipate.
  • The analysis capability itself has credible open source equivalents in Nextflow and Cromwell on raw cloud, so you are principally paying for compliance and governance rather than for the science.
  • Pipelines are built around Common Workflow Language, which is a real learning curve and a portability commitment for teams whose existing work is in other workflow languages.
  • Cloud storage of large genomic datasets accrues continuously whether or not you are analysing, and egress charges apply when moving results out, both of which are outside the subscription line.

Pricing, plan by plan

Dotmatics

On request
  • Dotmatics platform$undefined/year
    • Enterprise informatics platform priced per user per year on quotation
    • Chemistry and biology registration, assay data and ELN modules scoped separately
    • Implementation and data migration services quoted as a separate programme

Seven Bridges

On request
  • Seven Bridges Platform$undefined/year
    • Platform subscription quoted through Velsera sales
    • Cloud compute and storage charged on consumption on top of the subscription
    • Cost predictor tools provided to estimate analysis spend in advance

Which should you pick?

Choose Dotmatics if

  • You need dotmatics platform.
  • You work on Web, Windows, macOS, On-premise.
  • You also want graphpad prism.
Dotmatics review

Choose Seven Bridges if

  • You need trusted research environment.
  • You work on Web, API, Cloud.
  • You also want cloud-agnostic.
Seven Bridges review

Questions people ask

Is Dotmatics or Seven Bridges better?
Neither clearly leads. Dotmatics starts at On request and Seven Bridges at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Dotmatics or Seven Bridges?
Dotmatics starts at On request and Seven Bridges at On request.
Does Dotmatics or Seven Bridges run on more platforms?
Dotmatics runs on Web, Windows, macOS, On-premise. Seven Bridges runs on Web, API, Cloud.
What is Dotmatics best used for?
Dotmatics is most often used for a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer, a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover, a university licensing labarchives across departments as an institutional electronic lab notebook, a biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement route. Of those, a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer and a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover are not what Seven Bridges is typically brought in for.
What can Dotmatics do that Seven Bridges cannot?
Dotmatics covers Dotmatics platform, GraphPad Prism, SnapGene, Geneious Prime and Biologics. Seven Bridges covers Trusted research environment, Cloud-agnostic, CWL pipelines, Compliance certifications.

Answered from the vendors’ own pages

Dotmatics: Who owns Dotmatics?

Siemens, which completed a 5.1 billion dollar acquisition on 1 July 2025. Dotmatics now sits inside Siemens Digital Industries Software.

Seven Bridges: Is Seven Bridges still sold?

Yes. It is sold by Velsera, formed in 2023 when Summa Equity merged Seven Bridges with Pierian and UgenTec. The Seven Bridges name was retained for the platform.

Dotmatics: Is GraphPad Prism a Dotmatics product?

Yes. So are SnapGene, Geneious, LabArchives, FCS Express, OMIQ, Protein Metrics, SoftGenetics and nQuery.

Seven Bridges: What compliance does it hold?

FedRAMP Moderate, SOC 2, HIPAA, GDPR, dbGaP and ISO 27001, 27017, 27018 and 27701, which is the usual reason institutions choose it over building on raw cloud.

Dotmatics: Do the products work together?

To varying degrees. They were acquired separately and integration across the portfolio is uneven, so verify the specific pair you care about before assuming it.

Seven Bridges: How is it priced?

Not published. Expect a platform subscription plus consumption charges for cloud compute and storage.

Dotmatics: Is enterprise pricing published?

No. The informatics platform is quoted per user per year with modules and services scoped separately.

Seven Bridges: Do I have to use a specific cloud?

No. The platform is cloud-agnostic and designed to bring analysis to where the data already resides.

Share

Related pages

More on Dotmatics

More on Seven Bridges

Keep looking

Other head to heads